| Literature DB >> 33808619 |
Paulina K Kęszycka1, Ewa Lange1, Danuta Gajewska1.
Abstract
Salicylic acid and its derivatives (including acetylsalicylic acid/aspirin) are popular in medicine. They also occur naturally in many food products. The aim of the study was to investigate the effect of the personalized low salicylate diet (PLSD) on the reduction of asthma, rhinosinusitis and urticaria symptoms in patients with hypersensitivity to aspirin (ASA) or nonsteroidal anti-inflammatory drugs (NSAIDs). To achieve the research goal, a prospective, nonrandomized, baseline-controlled intervention study was conducted. Thirty patients diagnosed with NSAIDs hypersensitivity, who despite pharmacotherapy had symptoms of hypersensitivity, were included in the study. The PLSD was recommended for all participants for a period of two to four weeks. The intensity of subjectively declared symptoms of asthma, rhinosinusitis and urticaria were measured before and after dietary intervention, using, respectively, the asthma control test (ACT), the sino-nasal outcome test (SNOT-22) and the four-item itch questionnaire (FIIQ). Diet adherence and salicylate intake were measured by a 3-day food record. The severity of symptoms improved significantly after the intervention. The median of the ACT score was 24 scores before and 25 after the dietary intervention (p < 0.002), the median of the SNOT-22 score was 25 before and 13 after a dietary intervention (p < 0.0002) and the median of the FIIQ score was 5 before and 0 after a dietary intervention (p < 0.0002). The intake of salicylates decreased from 0.79 mg/day (before intervention) to 0.15 mg/day (p < 0.001) (during intervention). Although the usefulness of a low salicylate diet in the treatment of salicylate hypersensitivity is controversial, the results of our study indicate that the PLSD may have a positive effect in reducing symptoms of salicylate hypersensitivity and could be an additional tool supporting the therapy of these patients.Entities:
Keywords: NERD; dietary salicylates; low salicylate diet; salicylate hypersensitivity
Year: 2021 PMID: 33808619 PMCID: PMC8003553 DOI: 10.3390/nu13030991
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Study design. PLSD—personalized low salicylate diet, ACT—asthma control test, SNOT-22—sino-nasal outcome test, FIIQ—four-item itch questionnaire.
Baseline characteristics of the study group, n = 30.
| Mean | SD | Min–Max | Median | |
|---|---|---|---|---|
| Age, years | 40.33 | 16.29 | 18.00–83.00 | 37.50 |
| Weight, kg | 63.36 | 10.17 | 47.00–83.70 | 62.55 |
| BMI, kg/m2 | 23.28 | 4.25 | 17.92–32.70 | 22.02 |
| Disease duration, years | 3.32 | 3.04 | 0.25–10.00 | 2.00 |
| Number of patients | Percent (%) | |||
| Smokers | 2 | 6.67 | ||
| Food allergies | 10 | 33.33 | ||
| Inhalation allergies | 4 | 13.33 | ||
| Contact allergies | 2 | 6.67 | ||
| No allergies | 14 | 46.67 | ||
| Family history of aspirin sensitivity | 7 | 23.33 | ||
| Symptoms | Number of patients | Percent (%) | ||
| Urticaria (only) | 2 | 6.67 | ||
| Rhinosinusitis (only) | 1 | 3.33 | ||
| Urticaria and asthma | 1 | 3.33 | ||
| Urticaria and rhinosinusitis | 7 | 23.33 | ||
| Asthma and rhinosinusitis | 6 | 20.00 | ||
| Urticaria, asthma and rhinosinusitis | 13 | 43.33 | ||
SD—standard deviation, BMI—body mass index.
Group of medication used by study participants.
| Group of Drugs | Number of Patients ( | Percent (%) |
|---|---|---|
| Antihistamines | 25 | 83.33 |
| Glucocorticosteroids | 21 | 70.00 |
| Leukotriene receptor antagonists | 5 | 16.67 |
| Hydroxyzine | 2 | 6.67 |
| Levothyroxine | 6 | 20.00 |
| Proton pump inhibitors | 3 | 10.00 |
| Beta-blockers | 2 | 6.67 |
| Statins | 1 | 3.33 |
| Anticoagulants 1 | 2 | 6.67 |
1 Acetylsalicylic acid was not declared as an anticoagulant by the study participants.
Intake of dietary salicylates before and after dietary intervention among study participants.
| Salicylate Intake ( | ||||
|---|---|---|---|---|
| Baseline | PLSD | Statistical | Δ PLSD vs. Baseline | |
| Mean, mg/day | 0.90 | 0.20 | −0.70 | |
| Median, mg/day | 0.79 | 0.15 | −0.60 | |
| Min, mg/day | 0.07 | 0.03 | −2.86 | |
| Max, mg/day | 2.94 | 0.79 | 0.14 | |
| SD | 0.58 | 0.19 | 0.61 | |
PLSD—personalized low salicylate diet, a—versus baseline, SD—standard deviation.
Comparison of the ACT scores, the SNOT-22 scores and the four-item itch questionnaire scores before and after dietary intervention.
| Participants | Initial Test before | Retest after |
| ∆ after vs. before Intervention | |
|---|---|---|---|---|---|
| ACT score | |||||
| All | Mean | 23.00 | 24.27 | 1.27 | |
| Median | 24.00 | 25.00 | 0.001332 | 0.00 | |
| Min | 15.00 | 17.00 | −1 | ||
| Max | 25.00 | 25.00 | 8 | ||
| SD | 2.75 | 1.66 | 2.02 | ||
| With asthma | Mean | 22.00 | 23.90 | 1.90 | |
| Median | 23.00 | 25.00 | 0.001332 | 1.00 | |
| Min | 15.00 | 17.00 | −1.00 | ||
| Max | 25.00 | 25.00 | 8.00 | ||
| SD | 2.90 | 1.94 | 2.22 | ||
| SNOT-22 score | |||||
| All | Mean | 28.97 | 17.13 | −12.07 | |
| Median | 24.50 | 13.00 | 0.000175 | −4.50 | |
| Min | 0 | 0 | −51.00 | ||
| Max | 76.00 | 76.00 | 11.00 | ||
| SD | 20.89 | 18.61 | 14.73 | ||
| With rhinosinusitis | Mean | 32.19 | 19.04 | −13.41 | |
| Median | 32.00 | 14.00 | 0.000175 | −9.00 | |
| Min | 5.00 | 1.00 | −51 | ||
| Max | 76.00 | 76.00 | 11 | ||
| SD | 19.47 | 18.67 | 14.94 | ||
| FIIQ score | |||||
| All | Mean | 5.90 | 2.43 | −3.57 | |
| Median | 5.00 | 0.00 | 0.000152 | −3.00 | |
| Min | 0 | 0 | −11 | ||
| Max | 17 | 14 | 3 | ||
| SD | 5.11 | 3.51 | 3.75 | ||
| With urticaria | Mean | 7.70 | 3.04 | −4.65 | |
| Median | 6.00 | 2.00 | 0.000152 | −5.00 | |
| Min | 0 | 0 | −11 | ||
| Max | 17.00 | 14.00 | 3 | ||
| SD | 4.60 | 3.78 | 3.72 | ||
1 verified using Wilcoxon signed-rank test; ACT—asthma control test, SNOT-22—sino-nasal outcome test, FIIQ—four-item itch questionnaire.
Figure 2Individual results of the study participants: (a) individual results of “asthma control test” (ACT) scores before and after dietary intervention, n = 20; (b) individual results of “sino-nasal outcome test” (SNOT-22) scores before and after dietary intervention, n = 27; (c) individual results of “four-item itch questionnaire” (FIIQ) scores before and after dietary intervention, n = 23; (d) individual salicylates intake before and after dietary intervention, n = 30.